Cardiol Therapeutics/$CRDL
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Cardiol Therapeutics
Cardiol Therapeutics Inc is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. Its primary small-molecule candidate, CardiolRx, targets inflammasome pathway activation, which is involved in the development of inflammation and fibrosis in conditions such as pericarditis, myocarditis, and heart failure. The CardiolRx program includes the completed Phase II MAVERIC-Pilot study and the ongoing Phase III MAVERIC trial for the treatment of pericarditis. The ARCHER program evaluated CardiolRx in acute myocarditis through a completed Phase II study. The company is also developing CRD-38, a novel subcutaneous drug formulation for treating inflammatory heart conditions, including heart failure.
Ticker
$CRDL
Sector
Primary listing
Employees
18
Headquarters
Oakville, Canada
Website
CRDL Metrics
BasicAdvanced
$147m
-
-$0.28
-
-
Price and volume
Market cap
$147m
52-week high
$1.71
52-week low
$0.88
Average daily volume
577k
Financial strength
Current ratio
4.387
Quick ratio
3.931
Long term debt to equity
0.317
Total debt to equity
0.481
Profitability
EBITDA (TTM)
-25.746
Management effectiveness
Return on assets (TTM)
-78.25%
Return on equity (TTM)
-173.96%
Valuation
Price to book
8.15
Price to tangible book (TTM)
8.15
Price to free cash flow (TTM)
-6.92
Free cash flow yield (TTM)
-14.45%
Free cash flow per share (TTM)
-0.188
Growth
Earnings per share change (TTM)
-17.91%
3-year earnings per share growth (CAGR)
-5.46%
What the Analysts think about CRDL
Analyst ratings (Buy, Hold, Sell) for Cardiol Therapeutics stock.
CRDL Financial Performance
Revenues and expenses
CRDL Earnings Performance
Company profitability
CRDL News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs